Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Developmental Biology of Gastrointestinal Hormones
The gut not only represents the largest endocrine organ of the human body but is also profoundly involved in the control of metabolism through peptide hormones. Therefore, gastrointestinal hormones are acting via autocrine, paracrine, and classical endocrine pathways and regulate e.g. digestion, hunger, and satiety. Furthermore, they are important regulators of body weight, growth, and glucose metabolism, as well as of mood and behavior. Physicians and scientists in the field of pediatric endocrinology and diabetes, as well as in pediatric gastroenterology, require an extensive understanding of the origin of enteroendocrine cells, factors controlling their differentiation, hormone gene expression, secretion, function and, finally, the complex interaction with other organs, especially the central nervous system. In order to meet these needs, experts in the field have written up-to-date, comprehensive, and illustrated reviews presenting the current knowledge in the field of gastrointestinal endocrinology with a pediatric view. Those reviews comprise this latest volume of Endocrine Development.
Dapagliflozin in Patients with Type 2 Diabetes Mellitus
Abstract: Aim To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods Data were pooled from 13 placebo-controlled trials of up to 24 weeks' duration (dapagliflozin, n = 2360; placebo, n = 2295). Larger placebo-/comparator-controlled pools of 21 (≤208 weeks; dapagliflozin, n = 5936; control, n = 3403) and 30 trials (≥12 weeks; dapagliflozin, n = 9195; control, n = 4629) assessed the rare adverse events (AEs) of diabetic ketoacidosis (DKA) and lower limb amputation, respectively. Results Over 24 weeks, the overall incidence of AEs and serious AEs (SAEs) was similar for ...
Effectiveness and Safety of IGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis
Abstract: Introduction iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) has demonstrated glycaemic efficacy and safety in adults with inadequately controlled type 2 diabetes mellitus (T2DM). Per the European Medicines Agency's product label, iGlarLixi should be injected once a day within 1 h prior to a meal, preferably the same meal every day when the most convenient meal has been chosen. It is however unknown whether iGlarLixi administration timing affects glycaemic control and safety, as clinical trial evidence is mainly based on pre-breakfast iGlarLixi administration. Therefore, we assessed the effectiveness and safety of iGlarLixi in clinical practice, according to its administrat...
